Last reviewed · How we verify
NCT07059819
Local Hyperthermia for the Treatment of Cervical Persistent High-risk Infection
NA trial testing Local hyperthermia device in Cervical Intraepithelial Neoplasia (CIN) in 400 participants. Enrolling by invitation.
1 October 2026
Quick facts
| Lead sponsor | First Hospital of China Medical University |
|---|---|
| Phase | NA |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 400 |
| Start date | 2 November 2024 |
| Primary completion | 1 October 2026 |
| Estimated completion | 1 October 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Local hyperthermia device
Conditions studied
- Cervical Intraepithelial Neoplasia (CIN) — all drugs for Cervical Intraepithelial Neoplasia (CIN) →
- Human Papillovirus — all drugs for Human Papillovirus →
Sponsor
First Hospital of China Medical University
Who can join
Adults 18 to 65, female only, with Cervical Intraepithelial Neoplasia (CIN) or Human Papillovirus. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Human papillomavirus(HPV) infect epithelial cells and have the capacity to stimulate cell abnormal hyperplasia, especially by those high-risk HPV types. HPV vaccine primarily targeting HPV6/11/16/18 has been available and makes it possible to prevent cervical cancer. However, a large population was left unvaccinated, specifically for those aged ones. In clinic, patients harboring high-risk HPV is quite prevalent in China or other developing nations. Removing the virus and prevention of malignant transformation is required. Mild local Hyperthermia with a certain temperature range has been successfully used in the treatment of some diseases. It has been utilized in the treatment of some neoplasm, fungal and HPV infections. Investigators' study found that local hyperthermia at 44°C could cleared HPV in more than half of the patients with HR-HPV in cervical area. So the purpose of the study is to evaluate the effective of local hyperthermia in the treatment of cervical intraepithelial neoplasias grade I and II after 3 months. Appropriate control arms were designed for different conditions.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07059819
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other First Hospital of China Medical University trials
Trials by the same sponsor.
- NCT07350486 — LLM-CoManage: Large Language Model-Enabled Co-Management of Hypertension, Diabetes, and Dyslipidemia · NA · not yet recruiting
- NCT07534865 — Hyperthermia Combined With Hydrogen Peroxide Microneedle Patch for Viral Warts · NA · recruiting
- NCT07476898 — Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window · Phase 3 · not yet recruiting
- NCT07319065 — Left Ventricular Myocardial Work for Predicting Response to CRT · not yet recruiting
- NCT07286812 — Digital Technology Combined With Blood Marker Screening and Diagnosis for Community Populations Based on Classification · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07059819 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by First Hospital of China Medical University
- Last refreshed: 13 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07059819.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing